CLAIMS

1. A compound of the Formula I



Formula I

wherein:

R1 is NHR10, (substituted or unsubstituted C_1-C_6alkyl)NHR10 or (unsubstituted or substituted C_3-C_8 cycloalkyl)NHR10;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydrogen, aryl, C_1-C_6alkylaryl, hydroxy, C_1-C_6alkoxy, unsubstituted or substituted C_1-C_6alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted C_2-C_6alkenyl, or R6 and R7 together with the carbon atom to

which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C_3-C_8 cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl, or unsubstituted or substituted C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2),-O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or $-CF_3$, and K2 is hydrogen, halo or $-CF_3$ or K1 and K2 together form a methylenedioxy group;

Q is $-S(O)_2-$ or $-C(O)-$; and

m is a number selected from 1 or 2;

provided that R1 is (substituted C_1-C_6alkyl)NHR10 or (unsubstituted or substituted C_3-C_8 cycloalkyl)NHR10; or

R5 is hydroxy,C_1-C_6alkoxy, or substituted C_1-C_6alkyl; or

R6 and R7 are independently unsubstituted or substituted C_1-C_6alkyl or unsubstituted or substituted C_2-C_6alkenyl with the proviso that at least one group is substituted; or

R6 is hydrogen and R7 is substituted C_1-C_6alkyl or substituted C_2-C_6alkenyl; or

R6 and R7 together with the carbon atom to which they are attached may form a substituted C_3-C_8 cycloalkyl group which is optionally partly unsaturated; or

R8 is substituted C_1-C_6alkyl, substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl or substituted C_1-C_6alkylaryl;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C_1-C_6alkylNHR10;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydroxy, C_1-C_6alkoxy, or substituted C_1-C_6alkyl;

R6 and R7 are independently hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2),-O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or $-CF_3$, and K2 is hydrogen, halo or $-CF_3$ or K1 and K2 together form a methylenedioxy group;

Q is $-S(O)_2-$ or $-C(O)-$;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

3. A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C_1-C_6alkylNHR10;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydrogen, aryl, C_1-C_6alkylaryl, hydroxy, C_1-C_6alkoxy, unsubstituted or substituted C_1-C_6alkyl;

R6 and R7 are independently hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is substituted C_1-C_6alkyl, substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl or substituted C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2),-O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or $-CF_3$, and K2 is hydrogen, halo or $-CF_3$ or K1 and K2 together form a methylenedioxy group;

Q is $-S(O)_2-$ or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

4. A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C_1-C_6alkylNHR10;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydrogen, aryl, C_1-C_6alkylaryl, hydroxy, C_1-C_6alkoxy, unsubstituted or substituted C_1-C_6alkyl;

R6 and R7 are independently unsubstituted or substituted C_1-C_6alkyl or unsubstituted or substituted C_2-C_6alkenyl with the proviso that at least one group is substituted; or

R6 is hydrogen and R7 is substituted C_1-C_6alkyl or substituted C_2-C_6alkenyl; or

or R6 and R7 together with the carbon atom to which they are attached may form a substituted C_3-C_8 cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl or unsubstituted or substituted C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2),-O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or $-CF_3$, and K2 is hydrogen, halo or $-CF_3$ or K1 and K2 together form a methylenedioxy group;

Q is $-S(O)_2-$ or $-C(O)-$;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

5. A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is (substituted C_1-C_6alkyl)NHR10 or (unsubstituted or substituted C_3-C_8 cycloalkyl)NHR10;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydrogen, aryl, C_1-C_6alkylaryl, hydroxy, C_1-C_6alkoxy, unsubstituted or substituted C_1-C_6alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted C_2-C_6alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C_3-C_8 cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl or unsubstituted or substituted C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2),-O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or $-CF_3$, and K2 is hydrogen, halo or $-CF_3$ or K1 and K2 together form a methylenedioxy group;

Q is $-S(O)_2-$ or $-C(O)-$;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

6. A compound according to claim 2 wherein R1 is



or a pharmaceutically acceptable salt or solvate thereof.

7. A compound according to claim 2 or 6 wherein R6 and R7 are each C_1-C_3 alkyl or form a five or six membered carbocyclic ring; or a pharmaceutically acceptable salt or solvate thereof.

8. A compound according to any one of claims 2,6 or 7 wherein R5 is hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

9. A compound according to any one of claims 2 or 6 to 8 wherein R8 is hydrogen, methyl, ethyl or benzyl, or a pharmaceutically acceptable salt or solvate thereof.

10. A compound according to claim 3 wherein R1 is



or a pharmaceutically acceptable salt or solvate thereof.

11. A compound according to claim 3 or 10 wherein R6 and R7 are each C_1-C_3 alkyl or form a five or six membered carbocyclic ring, or a pharmaceutically acceptable salt or solvate thereof.

12. A compound according to any one of claims 3, 10 or 11 wherein R5 is hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

13. A compound according to any one of claims 3 or 10 to 12 wherein R8 is C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

14. A compound according to claim 4 wherein R1 is



or a pharmaceutically acceptable salt or solvate thereof.

15. A compound according to claim 4 or 14 wherein R6 and R7 are independently C_1-C_6alkyl or C_2-C_6alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C_1-C_6alkyl, C_2-C_6alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a C3-C8cycloalkyl group which is

optionally partly unsaturated and which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

16. A compound according to any one of claims 4,14 or 15 wherein R5 is hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

17. A compound according to any one of claims 4 or 14-16 wherein R8 is hydrogen, C_1-C_6alkyl, (C_1-C_6alkyl)C_3-C_8cycloalkyl, benzyl, 1-phenylethyl, C_1-C_6alkyl which is substituted by hydroxy, methoxy, $CONH_2$, or $CON(CH_3)_2$, or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

18. A compound according to claim 5 wherein R1 is selected from $-C(CH_3)(CH_2OH)NH_2$, $-C(CH_2F)_2NH_2$, $-C(CH_2F)(CH_2CH_2F)NH_2$, $-C(CF_3)(CH_3)NH_2$, $-C(CH_2CH_2F)_2NH_2$,





$-C(CH_2CH_3)(CH_2CF_3)NH_2$,

or a pharmaceutically acceptable salt or solvate thereof.

19. A compound according to claim 5 or 18 wherein R6 and R7 are each C_1-C_3 alkyl or form a five or six membered carbocyclic ring; or R6 and R7 are independently C_1-C_6alkyl or C_2-C_6alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C_1-C_6alkyl, C_2-C_6alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon

atom to which they are attached may form a C3-C8cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms;
or a pharmaceutically acceptable salt or solvate thereof.

20. A compound according to any one of claims 5,18 or 19 wherein R5 is hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

21. A compound according to any one of claims 5 or 18 to 20 wherein R8 is hydrogen, C_1-C_6alkyl, benzyl, C_1-C_6alkyl which is substituted by hydroxy, C_1-C_6alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

22. A compound according to any one of claims 1 to 21 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in any one of claims 1 to 21 or a pharmaceutically acceptable salt or solvate thereof.

23. A compound according to any one of claims 1 to 22 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl; or a pharmaceutically acceptable salt or solvate thereof.

24. A compound according to claim 23 wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C_1-C_6alkylaryl or unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C_1-C_6 alkyl, -OC_1-C_6 alkyl, -OCF_3, amide, aryl, aryloxy, SO_2(C_{1-6} alkyl), SO_2CF_3, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt or solvate thereof.

25. A compound according to any one of claims 1 to 24 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C_1-C_6 alkylaryl group or an unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group wherein:

the C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6 alkylaryl group is methyl, ethyl or propyl;

the C_1-C_6alkyl(O)- C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group is a moiety of formula $-CH_2OCH_2-$;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo (preferably chloro or fluoro), methyl, methoxy, cyano, SO_2Me, trifluoromethyl, and trifluoromethoxy. Most preferably the unsubstituted aryl moiety is phenyl, naphthyl, thiazolyl or indolyl and the substituted aryl moiety in said groups is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,6-trifluorophenyl, 2,3,4-trifluorophenyl, 2,4,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,3,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-methylphenyl, 2,6-difluoro-3-methylphenyl, 3,6-difluoro-2-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2,6-difluoro-3-chlorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyl, 2-chloro-3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, and 2-methyl thiazolyl.;

or a pharmaceutically acceptable salt or solvate thereof.

26. A compound according to any one of claims 1 to 25 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C_1-C_6alkylaryl, C_1-C_6alkyl(O)-C_1-C_6alkylaryl, C_3-C_8 cycloalkyl, (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolyl, indolinyl, (C_1-C_6 alkyl) indolyl.

27. A compound according to any one of claims 1 to 26 wherein R4 is hydrogen or methyl, or a pharmaceutically acceptable salt or solvate thereof.

28. A compound according to any one of claims 1 to 27 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, $CONH_2$, furanyl, benzothiophenyl and benzofuranyl;
or a pharmaceutically acceptable salt or solvate thereof.

29. A compound of according to claim 28 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, thiazolyl, pyridyl, phenoxy, 4-

chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, oxazolyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl;
or a pharmaceutically acceptable salt or solvate thereof.

30. A pharmaceutical formulation comprising one or more compounds according to any one of claims 1 to 29 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

31. A pharmaceutical formulation according to claim 30 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

32. A process for producing a compound of Formula I as defined in any one of claims 1 to 29 comprising coupling a compound of Formula XI or XIb



XI



XI b

with a compound of formula XIII



XIII

wherein R1, R2, R3, R4, R5, R6, R7, R8 , R9 and Q are as defined in any one of claims 1 to 29.

33. A process for producing a compound of Formula I as defined in any one of claims 1 to 29 comprising deprotecting a compound of Formula



wherein R2, R3, R4, R5, R6, R7, R8 , R9, m and Q are as defined in any one of claims 1 to 29, and PG is an amino protecting group.

34. A process for producing a compound of Formula I as defined in any one of claims 1 to 29 comprising coupling a compound of Formula



with a compound of formula XIV

HOOC—R1

XIV

wherein R1, R2, R3, R4, R5, R6, R7, R8 , R9 and Q are as defined in any one of claims 1 to 29.

35. A compound according to any one of claims 1 to 29 for the treatment of the human or animal body by therapy.

36. Use of a compound according to any one of claims 1 to 29 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a physiological condition which may be modulated or ameliorated by an increase in endogenous growth hormone.

37. A method of using a compound of any one of claims 1 to 5 or a pharmaceutically acceptable salt or solvate thereof for the treatment of a physiological condition which may be modulated or ameliorated by an increase in endogenous growth hormone, which method comprises administering to an animal in need of said treatment an effective amount of a compound of formula I.